Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …

Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …

Post-acute sequelae of COVID-19 (PASC) is emerging as global problem with unknown
molecular drivers. Using a digital epidemiology approach, we recruited 8,077 individuals to …

Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …

A hyperinflammatory response during severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection crucially worsens clinical evolution of coronavirus disease 2019 …

Unusually for a viral infection, the immunological phenotype of severe COVID-19 is
characterised by a depleted lymphocyte and elevated neutrophil count, with the neutrophil …

Critical COVID-19 patients admitted to the intensive care unit (ICU) frequently suffer from
severe multiple organ dysfunction with underlying widespread cell death. Ferroptosis and …

Since the identification of SARS-CoV-2 at the end of 2019, the coronavirus disease 2019
(COVID-19) pandemic has affected more than 410 million people worldwide and killed …

Background Randomized controlled trials (RCT) established the mortality reduction by
tocilizumab (Actemra), baricitinib (Olumiant), and sarilumab (Kevzara) in hospitalized COVID …

The current pandemic due to the SARS-CoV-2 virus has caused irreparable damage
globally. High importance is placed on defining current therapeutics for Coronavirus …